1. CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products
CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products (A, B) CAR T cell dose indicated in the study description of published CAR T cell gene therapy trials or trials registered at ClinicalTrials.gov. The CAR T cell dose is normalized to 75 kg or 1.72 m2 per dose. CAR T cells are either administered as a fixed dose (A) or in a dose escalation regimen (B). Each dot represents a single trial. (C, D) The reported number of CAR‐positive cells as given in Datasets EV3 and EV4 in column “%CAR+ cells (median; range)” was used to identify the median amount of CAR‐positive T cells in the various cell products within one clinical trial (C) and the range of variability between cell products within one clinical trial (lowest (min) and highest (max) percentage CAR‐positive T cells per trial) (D).
Jessica Hartmann et al. EMBO Mol Med. 2017;emmm
© as stated in the article, figure or figure legend